Neglected Tropical Disease Elimination — 2026-09-12
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Timor-Leste has officially been validated by the WHO for eliminating trachoma as a public health problem, marking the completion of this goal across the entire South-East Asia Region. Meanwhile, Paraguay is advancing toward similar validation following a recent technical mission by PAHO/WHO, signaling continued momentum in the Americas.
Neglected Tropical Disease Elimination — 2026-09-12
Top developments
Timor-Leste Validated for Trachoma Elimination
On September 3, 2026, the World Health Organization (WHO) validated Timor-Leste as having eliminated trachoma as a public health problem. This milestone is significant because it means trachoma has now been eliminated as a public health problem throughout the entire WHO South-East Asia Region. The validation follows decades of sustained national effort and international support to reduce the prevalence of the eye infection.
Paraguay Advances Toward Trachoma Validation
From August 24–27, 2026, the Pan American Health Organization/World Health Organization (PAHO/WHO) conducted a Technical Mission with Paraguay’s Ministry of Public Health and Social Welfare. The mission concluded on August 31, 2026, defining the next steps for Paraguay’s process toward validation of trachoma elimination as a public health problem. If successful, Paraguay will join the growing list of countries in the Americas to achieve this status, contributing to regional elimination targets.
Guinea Worm Cases at Historic Low
While not a new announcement within the strict 7-day window, the context of Guinea worm eradication remains critical. The CDC reported that only 10 human cases were recorded worldwide in 2025, the lowest annual total ever. This near-eradication status places immense pressure on surveillance systems in remaining endemic areas to prevent resurgence and achieve final certification. The focus for 2026 remains on maintaining zero transmission in Chad, Ethiopia, Mali, and South Sudan.
Local view
No recent local-language media coverage or stakeholder statements published after September 5, 2026, were available in the search results. Most relevant local coverage from Togo and other African nations dates back to June 2026, which falls outside the current freshness window.
Context & numbers
The global effort against NTDs has reached historic milestones, with 64 countries now having eliminated at least one NTD. The WHO and Gilead Sciences renewed their partnership in May 2026 through a new five-year agreement (2026–2030) to support visceral leishmaniasis elimination, ensuring continued drug access and technical support. However, funding gaps remain a concern, with reports indicating that ODA cuts may jeopardize the supply of donated drugs for diseases like river blindness and schistosomiasis.
On the radar
- Paraguay Validation Timeline: Watch for the official PAHO/WHO decision on Paraguay’s trachoma elimination validation, expected to follow up on the August 2026 technical mission findings.
- DNDi Leishmaniasis Results: The Phase 1 trial results for DNDI-6899, a potential oral treatment for visceral leishmaniasis, are anticipated in Q3 2026, which includes September. This could significantly impact treatment protocols if successful.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
